<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163472</url>
  </required_header>
  <id_info>
    <org_study_id>ECM 4 (J)</org_study_id>
    <nct_id>NCT03163472</nct_id>
  </id_info>
  <brief_title>Effect of Local Anaesthetic Volume on Axillary Brachial Plexus Block Duration</brief_title>
  <official_title>A Comparison of the Effects of Two Volumes (10 vs 30 mL) of Lidocaine 2% With Epinephrine 1:200 000 on the Duration of Ultrasound Guided Axillary Brachial Plexus Block.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cork University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cork University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Axillary brachial plexus block is an safe, effective and widely used technique for providing&#xD;
      surgical anesthesia at and below the elbow. Inadvertent intraneural and intravascular&#xD;
      injections are the only significant risks. Traditionally, greater volumes of local&#xD;
      anaesthetic have been administered to achieve successful axillary brachial plexus block, but&#xD;
      recent studies have demonstrated that this can be achieved with even very low volumes of 2-4&#xD;
      mL lidocaine 1.5% per nerve or ultra low volume of 1 mL lidocaine 2% per nerve.&#xD;
&#xD;
      Administration of 30mL (vs 10 mL) lidocaine 2% with epinephrine 1:200 000 prolongs the&#xD;
      sensory and motor block duration of ultrasound guided axillary brachial plexus block for&#xD;
      elective upper limb surgical procedures.&#xD;
&#xD;
      Primary Outcome:&#xD;
&#xD;
      The primary outcome will be the overall duration of sensory block.&#xD;
&#xD;
      Secondary Outcomes:&#xD;
&#xD;
      Duration of motor block Time to onset of the block. The quality of block intraoperatively&#xD;
      Time to first request of postoperative opioid analgesia. Total opioid consumption at 24&#xD;
      hours. The incidence of adverse effects perioperatively: nausea, dizziness, tinnitus,&#xD;
      vomiting, convulsions or arrhythmia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral nerve blocks provide significant benefits to patients, including improved&#xD;
      analgesia and decrease in general anaesthesia-related adverse effects. Ideally peripheral&#xD;
      nerve block provides rapid onset and substantial perioperative analgesia. Use of ultrasound&#xD;
      guidance in peripheral nerve blocks offers significant advantages compared to alternative&#xD;
      techniques. It improves block success rate and shortens onset time.&#xD;
&#xD;
      To compare the effects of local anaesthetic volumes (10 vs 30 mL) of lidocaine 2% with&#xD;
      epinephrine 1:200 000 on the duration of sensory and motor block following ultrasound guided&#xD;
      axillary brachial plexus block.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      It is a prospective, randomized, observer blinded study. With institutional ethical approval&#xD;
      and having obtained written informed consent from each, 30 patients will be studied.&#xD;
&#xD;
      Randomization and blinding:&#xD;
&#xD;
      Using a computer generated and sealed envelope technique, 30 patients will be randomly&#xD;
      allocated in to one of two groups.&#xD;
&#xD;
      Group 1: patients will receive 10 ml of lidocaine 2% with epinephrine. Group 2: patients will&#xD;
      receive 30 ml of lidocaine 2% with epinephrine.&#xD;
&#xD;
      Sample size and statistical analysis:&#xD;
&#xD;
      Sample size calculation will be based on duration of sensory block as the primary outcome&#xD;
      parameter. Kaabachi et al found a sensory duration of axillary brachial plexus block (with 30&#xD;
      mL of lidocaine 1.5%) of 126 (SD=48) mins. The minimum sample size required to have a 90%&#xD;
      probability of detecting a decrease in duration of 60 mins (level of significance 0.05) will&#xD;
      be 13 patients per group using an unpaired student's t test. Total recruited 30.&#xD;
&#xD;
      Anaesthetic procedure:&#xD;
&#xD;
      Having established intravenous access, standard anaesthetic monitoring will be applied.&#xD;
      Premedication with midazolam will be administered as clinically indicated (to a maximum of 3&#xD;
      mg). The operative arm will be abducted and externally rotated with elbow flexed at 90&#xD;
      degrees. Under strict aseptic condition, ultrasound guided axillary brachial plexus block&#xD;
      will be performed. Having identified musculocutaneous, median, radial and ulnar nerves, a&#xD;
      50mm 22-gauge ultraplex short bevel insulated needle will be used with in-plane approach to&#xD;
      block each nerve with either 2.5 ml (10 mL group) or 7.5 ml (30 mL group). All blocks will be&#xD;
      performed by single operator experienced in the ultrasound peripheral nerve blocks.&#xD;
&#xD;
      Block assessment:&#xD;
&#xD;
      When the block procedure has been completed, a blinded observer will assess the onset of&#xD;
      sensory and motor block15 in the innervation of each nerve every 5 mins, until surgical&#xD;
      anesthesia is achieved or 30 mins have elapsed. Surgical anesthesia will be defined as a&#xD;
      motor score ≤2, with absent sensation to cold and pinprick. Each nerve distribution will be&#xD;
      individually assessed. Onset time will be measured from conclusion of the block (t=0) to&#xD;
      attainment of surgical anesthesia. Block will be deemed failure if surgical anesthesia has&#xD;
      not been achieved at 30 mins in one or more of the four nerve distribution. In case of&#xD;
      failure, an additional rescue block or conversion to general anesthesia will be performed.&#xD;
      Data from these patients will be analysed separately.&#xD;
&#xD;
      Intraoperative period:&#xD;
&#xD;
      All patients will receive 1 g of paracetamol and diclofenac 75 mg iv during surgery. In case&#xD;
      of patients discomfort sedation and rescue analgesia in the form of fentanyl 25 micrograms&#xD;
      aliquots IV will be administered to a maximum of 100 micrograms.&#xD;
&#xD;
      Postoperative period:&#xD;
&#xD;
      Upon arrival to recovery room, sensory and motor function will be assessed every 15 mins by a&#xD;
      blinded observer.15 Assessment will be performed for each nerve separately. Block regression&#xD;
      is defined as a return of sensation to cold and pinprick with motor power score ≥3 in any&#xD;
      nerve region. Time to first request of postoperative analgesia and total opioid consumption&#xD;
      for 24 hrs will be noted. Postoperative analgesia will be prescribed as paracetamol 1 g 6&#xD;
      hourly and diclofenac sodium 75 mg 12 hourly. Oxycodone 5-10 mg orally 4-6 hourly will be&#xD;
      administered as rescue analgesia.&#xD;
&#xD;
      Primary Outcome:&#xD;
&#xD;
      The primary outcome will be the overall duration of sensory block.&#xD;
&#xD;
      Secondary Outcomes:&#xD;
&#xD;
      Duration of motor block Time to onset of the block. The quality of block intraoperatively&#xD;
      Time to first request of postoperative opioid analgesia. Total opioid consumption at 24&#xD;
      hours. The incidence of adverse effects perioperatively: nausea, dizziness, tinnitus,&#xD;
      vomiting, convulsions or arrhythmia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2012</start_date>
  <completion_date type="Actual">August 7, 2013</completion_date>
  <primary_completion_date type="Actual">August 7, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Duration of Sensory Block.</measure>
    <time_frame>24 hours</time_frame>
    <description>Duration of sensory block of ultrasound guided brachial plexus block</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Motor Block</measure>
    <time_frame>24 hours</time_frame>
    <description>The total duration of motor block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of the Block</measure>
    <time_frame>6 hours</time_frame>
    <description>Time to overall onset time for block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Request of Postoperative Opioid Analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Post-operative, Time to first request of opioid analgesia by the participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>overall cumulative opioid consumption dose of the participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Effects Perioperatively: Nausea, Dizziness, Tinnitus, Vomiting, Convulsions or Arrhythmia&quot;</measure>
    <time_frame>24 hours</time_frame>
    <description>We recorded the the number of participants with adverse effects like nausea, dizziness, tinnitus, vomiting, convulsions or arrhythmia during the perioperative period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Brachial Plexus Blockade</condition>
  <arm_group>
    <arm_group_label>10 ml of lidocaine 2% with epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30ml of lidocaine 2% with epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary brachial plexus block with 10 mL oof local anaesthetic</intervention_name>
    <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
    <arm_group_label>10 ml of lidocaine 2% with epinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary brachial plexus block with 30 ml of local anaesthetic</intervention_name>
    <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
    <arm_group_label>30ml of lidocaine 2% with epinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  ASA 1-3&#xD;
&#xD;
          -  Patients aged &gt;18 years&#xD;
&#xD;
          -  undergoing elective upper limb (forearm, wrist or hand) surgical procedures.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Contraindications to regional anaesthesia&#xD;
&#xD;
          -  Hypersensitivity to amide local anaesthetics.&#xD;
&#xD;
          -  Chronic pain&#xD;
&#xD;
          -  Language barrier&#xD;
&#xD;
          -  Neuromuscular disorders or peripheral neuropathy&#xD;
&#xD;
          -  Body mass index &gt; 35&#xD;
&#xD;
          -  History of hepatic and renal insufficiency&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cognitive or psychiatric disorder&#xD;
&#xD;
          -  Cardiac conduction abnormality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Ranganath, FCAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cork University Hospital</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 7, 2017</study_first_submitted>
  <study_first_submitted_qc>May 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <results_first_submitted>August 5, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2021</results_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cork University Hospital</investigator_affiliation>
    <investigator_full_name>Dr Anil Ranganath</investigator_full_name>
    <investigator_title>Dr (Fellow in Regional Anaesthesia)</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Assessed for eligibility: n= 60&#xD;
Excluded : n=30&#xD;
Not meeting inclusion criteria: n = 5&#xD;
Declined to participate: n= 25</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>10ml of Lidocaine 2% With Epinephrine</title>
          <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
        </group>
        <group group_id="P2">
          <title>30ml of Lidocaine 2% With Epinephrine</title>
          <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 ml of Lidocaine 2% With Epinephrine</title>
          <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
        </group>
        <group group_id="B2">
          <title>30ml of Lidocaine 2% With Epinephrine</title>
          <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="15.1"/>
                    <measurement group_id="B2" value="50" spread="22.1"/>
                    <measurement group_id="B3" value="49.3" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Duration of Sensory Block.</title>
        <description>Duration of sensory block of ultrasound guided brachial plexus block</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10 ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block with 10 mL oof local anaesthetic: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
          </group>
          <group group_id="O2">
            <title>30ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block with 30 ml of local anaesthetic: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Duration of Sensory Block.</title>
          <description>Duration of sensory block of ultrasound guided brachial plexus block</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" lower_limit="142" upper_limit="172"/>
                    <measurement group_id="O2" value="188" lower_limit="173" upper_limit="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Motor Block</title>
        <description>The total duration of motor block</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10 ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block with 10 mL oof local anaesthetic: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
          </group>
          <group group_id="O2">
            <title>30ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block with 30 ml of local anaesthetic: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Motor Block</title>
          <description>The total duration of motor block</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" lower_limit="147" upper_limit="180"/>
                    <measurement group_id="O2" value="195" lower_limit="175" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of the Block</title>
        <description>Time to overall onset time for block</description>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
          </group>
          <group group_id="O2">
            <title>30ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of the Block</title>
          <description>Time to overall onset time for block</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O2" value="10" lower_limit="5" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Request of Postoperative Opioid Analgesia</title>
        <description>Post-operative, Time to first request of opioid analgesia by the participants</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
          </group>
          <group group_id="O2">
            <title>30ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Request of Postoperative Opioid Analgesia</title>
          <description>Post-operative, Time to first request of opioid analgesia by the participants</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" lower_limit="168" upper_limit="224"/>
                    <measurement group_id="O2" value="267" lower_limit="224" upper_limit="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption</title>
        <description>overall cumulative opioid consumption dose of the participants</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
          </group>
          <group group_id="O2">
            <title>30ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>overall cumulative opioid consumption dose of the participants</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="5.6"/>
                    <measurement group_id="O2" value="6.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Effects Perioperatively: Nausea, Dizziness, Tinnitus, Vomiting, Convulsions or Arrhythmia&quot;</title>
        <description>We recorded the the number of participants with adverse effects like nausea, dizziness, tinnitus, vomiting, convulsions or arrhythmia during the perioperative period.</description>
        <time_frame>24 hours</time_frame>
        <population>No adverse events noted in any participants in either group</population>
        <group_list>
          <group group_id="O1">
            <title>10 ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block with 10 mL oof local anaesthetic: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
          </group>
          <group group_id="O2">
            <title>30ml of Lidocaine 2% With Epinephrine</title>
            <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block with 30 ml of local anaesthetic: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Effects Perioperatively: Nausea, Dizziness, Tinnitus, Vomiting, Convulsions or Arrhythmia&quot;</title>
          <description>We recorded the the number of participants with adverse effects like nausea, dizziness, tinnitus, vomiting, convulsions or arrhythmia during the perioperative period.</description>
          <population>No adverse events noted in any participants in either group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>The Incidence of Adverse Effects peri-operatively: Nausea, Dizziness, Tinnitus, Vomiting, Convulsions or Arrythmia</desc>
      <group_list>
        <group group_id="E1">
          <title>10ml of Lidocaine 2% With Epinephrine</title>
          <description>patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.</description>
        </group>
        <group group_id="E2">
          <title>30ml of Lidocaine 2% With Epinephrine</title>
          <description>patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.&#xD;
Axillary brachial plexus block: patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Anil Ranganath</name_or_title>
      <organization>Cork University Hospital</organization>
      <email>drmrak.2@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

